Racial Differences in Atrial Fibrillation Management Between White Patients and Black Patients in Transthyretin Cardiac Amyloid
Section snippets
Methods
This study included a retrospective cohort of 558 patients diagnosed with ATTR-CA. Patients were included from Cardiac Amyloidosis Programs at 3 sites from 2001 to 2020 over 19 years. The cohort is representative of an international sample. The institutional review boards across each site approved the study. This study was a retrospective review that was exempt from written informed consent.
Patients were diagnosed with ATTR-CA based on tissue biopsy or scintigraphy.2 Tissue biopsies were either
Results
The study included 558 patients diagnosed with ATTR-CA, for which Table 1 indicates baseline characteristics. A total of 488 patients (87.5%) identified as White, whereas 70 patients (12.5%) identified as Black. All the Black patients were from the New York City site. There were 367 White patients (75%) diagnosed with AF compared with 39 Black patients (56%) diagnosed with AF at any point (p = 0.001). Of White patients with AF, 326 (89%) were diagnosed with ATTRwt compared with 8 Black patients
Discussion
This study examines the differences in race and outcomes of thromboembolic events in patients with ATTR-CA and AF. The major findings are: (1) in patients with ATTR-CA, Black patients had less prevalent and incident AF than White patients, (2) despite Black patients having a lower prevalence of AF, they had a higher incidence of thromboembolic events than White patients and decreased time to combined thromboembolic event that was at least, in part, mediated by lower use of anticoagulation and
Disclosures
Dr. Maurer reports financial support was provided by National Institute on Aging; reports a relation with Pfizer and Alnylam Pharmaceuticals Inc. that includes: board membership and funding grants; reports a relation with Ackea, Ionis Pharmaceuticals Inc., Prothena Biosciences Inc., Eidos, and GalaxoSmithKline that includes: board membership. Dr. Gonzalez-Lopez reports financial support was provided by Carlos III Health Institute; reports a relation with Pfizer that includes: consulting or
Reference (30)
- et al.
Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review
J Am Coll Cardiol
(2019) - et al.
The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients
Am J Med
(1977) - et al.
Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies
JACC Clin Electrophysiol
(2020) - et al.
Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement
Am J Cardiol
(2005) - et al.
Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study
Am Heart J
(2009) - et al.
Atrial fibrillation and ischemic stroke With the amyloidogenic V122I transthyretin variant among black Americans
J Am Coll Cardiol
(2021) - et al.
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score
Chest
(2013) - et al.
Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis
JACC Cardiovasc Imaging
(2022) - et al.
Too stiff but still got rhythm: left atrial myopathy and transthyretin cardiac amyloidosis
JACC Cardiovasc Imaging
(2022) - et al.
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
Eur Heart J
(2021)
Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis
Circulation
Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation
Circulation
Diagnosis and management of the cardiac amyloidoses
Circulation
Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience
ESC Heart Fail
Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role
Amyloid
Cited by (1)
Regional and Demographic Disparities in Atrial Fibrillation Mortality in the USA
2024, Journal of Racial and Ethnic Health Disparities
Dr. Maurer is funded by K24-AG036778 from the National Institute on Aging, Bethesda, Maryland. This study has been partially funded by Instituto de Salud Carlos III, Madrid, Spain through the projects PI18/0765 (to Dr. Gonzalez-Lopez) and PI20/01379 (to Dr. Garcia-Pavia). These projects are co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/”Investing in your future.”